27 completed, 7 terminated, 5 unknown, 3 withdrawn. 44 Phase 2, 18 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Completed 27, Terminated 7, Unknown 5, Withdrawn 3, Recruiting 1, Suspended 1 |
| Phase 1 | 18 | Completed 9, Terminated 5, Unknown 3, Recruiting 1 |
Follow B-Cell Chronic Lymphocytic Leukemia: new trials by email Literature Review of B-Cell Chronic Lymphocytic Leukemia trials Research Report on B-Cell Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine - Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2024-09-03 | 2026-10-16 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL PBCAR20A, Fludarabine, Cyclophosphamide - Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | Phase 1 / Phase 2 | Completed | Precision BioSciences, Inc. | 18 | 2020-03-24 | 2023-01-31 |
| Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia Ibrutinib, Obinutuzumab, Venetoclax - B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis) | Phase 2 | Completed | Grupo Cooperativo de Hemopatías Malignas | 3 | 2018-12-01 | 2021-02-02 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Oncternal Therapeutics, Inc | 95 | 2018-01-03 | 2025-02-12 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib, Fludarabine, Pembrolizumab - B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-09-22 | 2026-01-30 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies T-cell therapy + Rituximab + IL-2 - B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | National University Hospital, Singapore | 18 | 2014-12-01 | 2016-06-22 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Rituximab in Pretreated Elderly or Unfit B-CLL Patients Rituximab, Glucocorticoid - B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Completed | Prof. Dr. Med. Laimonas Griskevicius | 25 | 2011-10-01 | 2019-12-27 |
| Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia Alemtuzumab - B-cell Chronic Lymphocytic Leukemia | Phase 2 | Suspended | Shanghai Zhangjiang Biotechnology Limited Company | 120 | 2011-07-01 | 2022-06-21 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL PCI-32765, ofatumumab - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 71 | 2010-12-01 | 2015-06-25 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia PCI-32765 - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Completed | Pharmacyclics LLC. | 199 | 2010-06-01 | 2020-05-27 |
| Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) bafetinib - B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Completed | CytRx | 20 | 2010-06-01 | 2013-05-15 |
| Safety of PCI-32765 in Chronic Lymphocytic Leukemia PCI-32765 - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 133 | 2010-05-01 | 2014-03-31 |
Showing 20 of 44. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (44) · Lymphoma, Follicular (13) · Lymphoma, Mantle-Cell (13) · Lymphoma, Large B-Cell, Diffuse (12) · Lymphoma, Non-Hodgkin (11) · Lymphoma, B-Cell, Marginal Zone (10) · Waldenstrom Macroglobulinemia (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Burkitt Lymphoma (7) · Lymphoma, Large-Cell, Immunoblastic (7) · Hodgkin Disease (6) · Intraocular Lymphoma (5) · Lymphoma, B-Cell (5) · Leukemia (4) · Leukemia, Hairy Cell (4)
Chronic Disease (44) · Disease Attributes (44) · Hematologic Diseases (44) · Hemic and Lymphatic Diseases (44) · Immune System Diseases (44) · Immunoproliferative Disorders (44) · Lymphatic Diseases (44) · Lymphoproliferative Disorders (44) · Neoplasms by Histologic Type (44) · Pathologic Processes (44) · Pathological Conditions, Signs and Symptoms (44) · Leukemia, Lymphoid (42) · Neoplasms (42) · Leukemia, B-Cell (41) · Leukemia (40)
Rituximab (11) · Alemtuzumab (6) · Cyclophosphamide (6) · ibrutinib (6) · fludarabine (5) · fludarabine phosphate (5) · alvocidib (3) · Bevacizumab (2) · Cyclosporine (2) · Flow Cytometry (2) · In Situ Hybridization, Fluorescence (2) · Peripheral Blood Stem Cell Transplantation (2) · Polymerase Chain Reaction (2) · Amplified Fragment Length Polymorphism Analysis (1) · CTLA-4 Antigen (1)
National Cancer Institute (NCI) (14) · Pharmacyclics LLC. (3) · Chinese PLA General Hospital (2) · Fred Hutchinson Cancer Center (2) · Abbott (1) · Alexion Pharmaceuticals, Inc. (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Asana BioSciences (1) · Chronic Lymphocytic Leukemia Research Consortium (1) · Cylene Pharmaceuticals (1) · CytRx (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Genitope Corporation (1) · German CLL Study Group (1) · Grupo Cooperativo de Hemopatías Malignas (1)
United States (30) · China (4) · Argentina (1) · Austria (1) · Germany (1) · Lithuania (1) · Mexico (1) · Singapore (1) · United Kingdom (1)
John Byrd (3) · Ajay Gopal (2) · Neil Kay (2) · Sonali Smith (2) · Tait Shanafelt (2) · Adrian U Wiestner, M.D. (1) · Alan List, MD (1) · Andreas Engert (1) · Anthony D Ho, Ph.D., Prof. (1) · Danelle James, M.D., M.A.S (1) · Daniel Levitt, M.D., Ph.D. (1) · David Maloney (1) · James Dean, MD (1) · James N Kochenderfer, M.D. (1) · John Pagel (1)
PMID 19826119, PMID 22289993, PMID 23886836, PMID 24990615, PMID 26182309, PMID 26813675, PMID 29437592, PMID 31196847, PMID 32209572, PMID 34515338, PMID 20837940, PMID 21072184, PMID 21508413, PMID 22584787, PMID 23547837, PMID 23782158, PMID 24332241, PMID 25381051, PMID 25444722, PMID 25596730, PMID 25724156, PMID 26116658, PMID 26213141, PMID 29263894, PMID 29470582, PMID 30454872, PMID 31443741, PMID 31481800, PMID 31671877, PMID 34398557, PMID 40720747, PMID 41804087, PMID 42827116
U10CA025224 (3), N01CM62202 (2), N01CM62207 (2), P30CA014599 (2), P30CA015083 (2), U10CA031946 (2), 2005 (1), 2014 (1), N01CM00039 (1), N01CM62201 (1), N01CM62205 (1), P01CA078902 (1), P30CA014236 (1), P30CA015704 (1), P30CA016058 (1)